Nicotine-Qbeta: Phase II start

Novartis will soon begin a U.S. Phase II trial to evaluate 4 monthly NIC002 vaccinations in 65 smokers. The pharma has exclusive, worldwide rights to the vaccine from Cytos under a 2007 deal (see BioC...